Q1 proved to be strong, beating consensus figures, with re-accelerating GMV and sales growth. The upgrade to FY 2024 sales guidance (with rising debate over the prospect of an EBITDA upgrade as well this year) strengthens our view that Delivery Hero deserves to rerate further beyond 0.9x EV/Sales g
Q1 2024 sales climbed by 54% (54% at CER) YoY and 7% QoQ, totalling SEK 184.4m. The US market, owing 77% of overall sales, was boosted by a 65% growth (65% at CER), with CERAMENT G being the major driver bringing SEK 92m sales (SEK 34.8m). EU showed a 27% YoY growth in sales, delivered by both prod
>EBIT T1 >3% au consensus - L’EBIT ressort à 532 MCHF (+16.3% à pcc et -8.3% en réel), au-dessus du consensus (515 MCHF) et de nos attentes (491 MCHFe). Le niveau de croissance en monnaie locale ressort à 17.1%, soit globalement en ligne avec le T4 (18.3%,) tiré par une contribution des acquisitions de 3.4% au T1. Par rapport à nos estimations, l’EBIT est supérieur à nos attentes dans toutes les divisions à l’exception de la branche Solution & Products (-4% vs nos est...
A director at Autobio Diagnostics Co Ltd maiden bought 901,200 shares at 55.820CNY and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the ...
A director at Svenska Handelsbanken AB (publ) bought 5,000 shares at 100.850SEK and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last...
>Opinion Neutre réitérée, objectif de cours calé sur l’offre du consortium - Believe a publié hier soir son CA T1 ressorti légèrement inférieur à notre attente avec une croissance organique ajustée de 16% alors que nous tablions sur 20%. Le 1er trimestre a donc été un peu plus mou qu’attendu. Le groupe a tenu sa conférence téléphonique dans la foulée durant laquelle il a indiqué tabler sur une accélération de la croissance organique sur le reste de l’année. Il confir...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.